Trial Profile
A 28-week, Multi-center Randomized, Double-blind, Placebo-controlled Study to Evaluate the Potential of Dapagliflozin Plus Exenatide in Combination With High-dose Intensive Insulin Therapy Compared to Placebo in Obese Insulin-resistant Patients With Type 2 Diabetes Mellitus (Proof-of-concept Study)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Exenatide (Primary) ; Insulin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- 29 Mar 2020 Status changed from recruiting to discontinued.
- 03 May 2018 Status changed from not yet recruiting to recruiting.
- 16 Feb 2018 Planned End Date changed from 15 Feb 2019 to 15 Jun 2019.